Hormonal
New-generation incretin-based obesity medications (semaglutide 2.4 mg weekly and tirzepatide 5-15 mg weekly) achieve mean weight loss exceeding 10-15%, which is two- to three-fold greater than previous obesity medications.
If you have obesity, new medications like semaglutide (2.4 mg weekly) or tirzepatide (5-15 mg weekly) can help you lose 15% or more of your body weight, which is significantly more than older drugs. These are taken as weekly injections. Because obesity is a chronic condition, you likely need to stay on these medications long-term to maintain the weight loss, similar to how you manage blood pressure or diabetes with daily meds.
For the first time, participants in clinical trials of these new agents achieved mean weight loss in excess of 10%, with loss of 15% for semaglutide 2.4 mg weekly and 15–21% for tirzepatide 5–15 mg over 68–72 weeks [13,14] – figures two-fold to three-fold larger than previously seen with obesity medications.
Why this rating
Based on large-scale randomized controlled trials (e.g., STEP, SURMOUNT) cited in the review.
Source
Medical management of obesity: unlocking the potential
Angie S. Xiang et al. · Climacteric · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →